Track record · closed signal

Pfizer Inc (PFE) — closed signal from April 30, 2026

Partial Published before the outcome was known, scored automatically when the window closed on July 29, 2026 — -2.3% at the close.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted

$24.12 – $25.15Entry zone — fair-value band

$25.75Published — price the day we called it

$26.89Target — the price the thesis aimed for

$26.08Peak — highest point inside the window, not a realized return

$25.15Window close — end-of-window price, context only

What happened

Partial

Reached 16% of the predicted growth at its peak, without hitting the target.

At window close

-2.3%

realized, from the publication price to the last close inside the window

Peak gain

+1.3%

peak, from the publication price — not a realized return

S&P 500, same window

+1.8%

SPY over the identical days, dividend-adjusted

Window close

$25.15

last close inside the window, ended July 29, 2026

Peak price

$26.08

peak on May 27, 2026 — not a realized return

Days to target

—

The thesis — published April 30, 2026

Predicted growth

+8%

over the measurement window

Target price

$26.89

the price the thesis aimed for

Entry zone

$24.12 – $25.15

the fair-value band we waited for

Price at publication

$25.75

published April 30, 2026

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Pfizer looks like a safer stock that could stop falling and settle down soon. News about a patent settlement for VYNDAMAX and repeated quarterly profits beating expectations support this view. Trading has been heavy and the stock looks oversold, so short-term stability is likely. Still, falling sales, debt, and limited upside keep expectations modest.

Primary drivers

Patent settlement lengthens product protection
Earnings beats show execution despite weak sales
Healthcare exposure tends to hold up in market stress
Lots more people trading the stock signals renewed attention

How it played out

PFE: target missed after a 1.3% peak gain

Lyra published PFE at $25.75 and expected 8% growth. The thesis expected the stock to stop falling and settle down. It pointed to longer patent protection, repeated earnings beats despite weak sales, defensive healthcare exposure, and heavy trading as signs of renewed attention. Debt and limited upside kept the forecast modest.

The stock rose to a peak of $26.08 on May 27, a 1.3% gain. It stayed below the $26.89 target and ended the window at $25.15. The stability part played out to a degree, but the expected gain did not. Overall, the thesis only partially played out.

What happened during the window

On May 5, Pfizer reported first-quarter 2026 results and reaffirmed its full-year 2026 guidance. On May 28, it announced a global oncology collaboration with Innovent Biologics.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals